Cost Effectiveness of Sunitinib As First-Line Targeted Therapy for Metastatic Renal Cell Carcinoma in China

Q. Shi,H. Yin,J. Xuan,Y. Wu,G. Cheng

DOI: https://doi.org/10.1016/j.jval.2014.08.2294

IF: 5.156

2014-01-01

Value in Health

Abstract:Multitargeted receptor tyrosine kinase inhibitors are more effective alternatives to interferon-α and monoclonal antibodies in patients with metastatic renal cell carcinoma (mRCC). However, studies on the economic and humanistic outcomes associated with these treatments are sparse in the Chinese setting. This study evaluated the clinical and economic consequences of sunitinib compared with sorafenib and interferon-α from the third-party payer’s perspective in China. A Markov model was developed to simulate disease progression and determine cost and outcomes over patient’s lifetime. The time horizon of analysis was patients’ lifetime with a maximum of five years in cycles of six weeks. The model was used to conduct a cost-utility analysis on sunitinib compared to interferon-α and sorafinib. Costs of physician, anti-cancer medications, hospitalization, laboratory, and palliative care were estimated. Outcomes were measured in progression-free life years (PFLYs), life years (LYs) and quality-adjusted life years (QALYs). A 3.5% discount rate was applied to both costs and QALYs gained. In the base case, the total cost of the sunitinib arm was RMB217,038.50, the progression-free life year was 1.57, life year was 2.55, and QALY was 1.70. The incremental cost per PFLY between sunitnib and IFN-α was –RMB78,562.10 and RMB 22,501.03 between sunitinib and sorafenib. The incremental cost per life year between sunitnib and IFN-α was –RMB168,633.00 and RMB 21,022.38 between sunitinib and sorafenib. The incremental cost per QALY between sunitnib and IFN-α was –RMB184,825.00 and RMB 29,493.42 between sunitinib and sorafenib. This economic study used the final clinical results of the pivotal sunitinib trial that provides more accurate modeling results than previous studies based on extrapolation. It was found that sunitinib was dominant compared to IFN-α. Sunitinib was cost effective compared to sorafenib based on the threshold recommended by the World Health Organization.